Fidson Healthcare Plc
Every TNI analysis that covers Fidson Healthcare Plc.
Nigerian Pharma 9M 2026 Scorecard: May & Baker Wins on Quality, Fidson on Scale, MeCure Carries the Debt
A calmer naira and lower FX losses lifted every listed drugmaker in 2026. Only May & Baker turned that into clean, cash-backed, cheaply priced earnings.
9 November 2026 · Read analysis →Fidson 9M 2026: Profit Up 47%, but FX Did Most of the Heavy Lifting
Fidson's 9M profit jumped 47% to N11.74bn, but about 69% of the pre-tax gain came from vanished FX losses while receivables and debt ballooned.
9 November 2026 · Read analysis →